Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
Analyzing fundamentals for CDIO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see CDIO Fundamentals page.
Watching at CDIO technicals we can see that long-term trend is bearish, while middle-term trend is bullish, as well as bullishshort-term trend. More technicals details can be found on CDIO Technicals page.
An error has occurred. This application may no longer respond until reloaded.